CNTX – context therapeutics inc. (US:NASDAQ)
Stock Stats
News
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.
Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]
Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]
Form S-8 Context Therapeutics
Form 8-K Context Therapeutics For: Mar 23
Form 10-K Context Therapeutics For: Dec 31
Form 8-K Context Therapeutics For: Mar 11
Form 8-K Context Therapeutics For: Feb 24
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.